COMPANY
Amygdala Neurosciences
We invented a compound, ANS-858, which is an orally bioavailable, selective, reversible ALDH2 inhibitor. We are developing medications that can be taken orally to suppress the craving and relapse associated with alcohol and other substance use disorders. From company website Source · Oct 13, 2026
Timeline
- Trial start Phase 1: A Study to Evaluate the Safety of the Coadministration of ANS-6637 and Ethanol source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT03203499 | A Study to Evaluate the Safety of the Coadministration of ANS-6637 and Ethanol | Phase 1 | Completed | Feb 27, 2017 | Nov 15, 2017 (actual) |